Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Net Income (2017 - 2025)

VYNE Therapeutics' Net Income history spans 9 years, with the latest figure at -$8000.0 for Q2 2025.

  • For Q2 2025, Net Income rose 27.27% year-over-year to -$8000.0; the TTM value through Dec 2025 reached -$24000.0, up 11.11%, while the annual FY2025 figure was $253000.0, 1037.04% up from the prior year.
  • Net Income reached -$8000.0 in Q2 2025 per VYNE's latest filing, roughly flat from -$8000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $13.4 million in Q1 2022 to a low of -$9.7 million in Q1 2021.
  • Average Net Income over 5 years is -$1.1 million, with a median of -$36000.0 recorded in 2023.
  • Peak YoY movement for Net Income: soared 238.14% in 2022, then crashed 151.47% in 2023.
  • A 5-year view of Net Income shows it stood at -$3.2 million in 2021, then surged by 31.71% to -$2.2 million in 2022, then surged by 98.35% to -$36000.0 in 2023, then soared by 77.78% to -$8000.0 in 2024, then changed by 0.0% to -$8000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Net Income are -$8000.0 (Q2 2025), -$8000.0 (Q1 2025), and -$8000.0 (Q4 2024).